As part of Goodwin’s week of exclusive programming during the BIO International Convention in Boston, we’re excited to invite you to a session focused on China-based NewCos and the dynamics of cross-border dealmaking. China continues to be a dynamic hub for biotech innovation, and companies operating in this space are navigating new opportunities and evolving challenges.
Join us for a morning of insightful conversations exploring what it takes to launch, grow, and expand China-based NewCos—and how to successfully pursue international transactions in a rapidly changing environment. From legal and regulatory foundations to cross-border growth strategies, our expert panels will share practical perspectives and real-world experience to help guide your next move.
Please RSVP here and see below for more details!
Date & Time: Tuesday, June 17 from 8:30 AM – 10:30 AM ET
Location: Goodwin’s Boston Office, 100 Northern Avenue. Boston, MA 02210
8:30 AM – 9:00 AM | Registration and Breakfast
9:00 AM – 9:05 AM | Welcome Remarks
9:05 AM – 9:45 AM | Panel: China NewCos – Strategic and Legal Insights
- Josha Berlin, Head of Corporate Alliances & Business Development, BioCentury Inc. (Moderator)
- David Chen, Partner, Goodwin
- Sue Yao, Executive Director of Licensing and Business Development, Kelun Biotech and Klus Pharma
- Regina Salvat, PhD, Principal, Forbion
9:50 AM – 10:30 AM | Panel: New Challenges and Opportunities in Cross-Border Transactions
- Wendy Pan, Partner, Goodwin (Moderator)
- Alan Wang, Partner, Goodwin
- Jimmy Zhuang, Assistant General Counsel – Business Development, Novo Nordisk
- Tim Opler, Managing Director, Healthcare, Stifel Institutional
- Jon Kiburz, VP Transactions, R&D Business Development, GSK
- Jesús Baena, Director BD&L Oncology, Novartis